Urine-Based HPV Test Has Entered Clinical Study
Researchers are evaluating a new screening method that could make cervical cancer testing more accessible for women.
Updated on Oct. 11, 2026 in Cancer
Live Poll
Would you prefer using home-collected samples for medical screenings over visiting a clinic?
Phase Scientific has begun a clinical study involving 17,000 women to evaluate a new urine-based HPV testing method. This technology aims to provide a less invasive alternative for cervical cancer screening compared to traditional clinical collection methods.
Why it matters
If successful, this urine-based screening could remove barriers for individuals reluctant to undergo standard procedures, potentially increasing participation in life-saving cervical cancer screenings. The research is being funded by the company's reinvested profits from pandemic-era rapid testing.
A clinical study is currently evaluating the effectiveness of a proprietary urine-based HPV screening method in a cohort of 17,000 women across mainland China. This study is testing whether the firm's concentration technology can effectively detect HPV markers in liquid samples.
The players
Phase Scientific
A biotechnology firm headquartered in Hong Kong that develops diagnostic testing technologies and previously produced rapid Covid-19 antigen tests.
University of Hong Kong
A research institution currently collaborating with Phase Scientific on a study investigating new diagnostic testing methods.
The details
The testing process utilizes proprietary concentration technology to process urine samples in a laboratory setting. By concentrating biological material from the liquid sample, the method is designed to identify HPV presence without requiring a physical pelvic exam. Phase Scientific is also investigating if this same concentration process might eventually be used to detect early-stage liver and lung cancers.
Timeline
2015: Phase Scientific was founded in California.
July 2021: The firm received US emergency-use authorization for its Indicaid rapid antigen test.
January 2025: Dennis Lo became vice-chancellor of the Chinese University of Hong Kong.
Health Landscape
This research follows a pattern set by the WHO cervical cancer elimination strategy, which emphasizes the need for expanded screening access to reduce mortality. It represents a potential shift toward non-invasive diagnostic tools that address common barriers in current cancer detection standards.
While this method is currently limited to a clinical study, advancements in urine-based screening may eventually offer a simpler, more accessible option for routine cancer detection. You should continue to follow current screening guidelines and discuss any concerns about testing procedures with your physician.
The takeaway
The move toward urine-based screening highlights how diagnostic technology can evolve to improve patient comfort and screening compliance. If you are due for a cervical cancer screening, consult your doctor about the most effective, evidence-backed testing options currently available for you.
Further reading
For more on evolving methods for detection and risk reduction, visit our Cancer section.
Source note: This article includes information reported by South China Morning Post.
Live Poll
Would you prefer using home-collected samples for medical screenings over visiting a clinic?
